BIGBEAR
PHARMACEUTICAL
Ivosidenib can reduce the production of the oncogenic metabolite 2-HG by selectively targeting and inhibiting the activity of the mutant IDH1 enzyme.
AuthenticGuaranteeFast DeliveryPrivacy May 2, 2019 (Global Newswire) — Cambridge, MAAgios Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved its supplem···【More】
Update: 06 May,2026Source: BigbearViews: 103
August 25, 2021 – BostonServier Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Ivosidenib for the treatment o···【More】
Update: 06 May,2026Source: BigbearViews: 104
May 25, 2022, BostonServier announced that the U.S. Food and Drug Administration (FDA) has approved ivonidenib in combination with azacitidine for the···【More】
Update: 06 May,2026Source: BigbearViews: 103
October 24, 2023, Boston, USAServier announced that the U.S. Food and Drug Administration (FDA) has approved ivonidenib for the treatment of patients ···【More】
Update: 06 May,2026Source: BigbearViews: 104
Ivosidenib is used to treat acute myeloid leukemia (AML), cholangiocarcinoma, and myelodysplastic syndromes (MDS) in adult patients with isocitrate de···【More】
Update: 06 May,2026Source: BigbearViews: 105
Ivosidenib Indications1. LeukemiaIvosidenib, used in combination with azacitidine or as monotherapy, is indicated for newly diagnosed acute myeloid le···【More】
Update: 09 Mar,2026Source: BigbearViews: 104
In addition to its expected therapeutic effects, some adverse side effects may occur during treatment with ivosidenib. While not all side effects will···【More】
Update: 09 Mar,2026Source: BigbearViews: 105
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
